FDA issues proposed rule for OTC skin bleaching products
The FDA has issued a notice of proposed rulemaking that would establish that OTC skin bleaching drug products are not generally recognized as safe and effective and are misbranded.
The FDA has issued a notice of proposed rulemaking that would establish that OTC skin bleaching drug products are not generally recognized as safe and effective and are misbranded. The agency is issuing this proposed rule after considering new data and information on the safety of hydroquinone, the only active ingredient that had been proposed for inclusion in a monograph for these products. Written or electronic comments may be submitted by Dec. 27. Comments may be submitted at www.regulations.gov.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
